CD8a (mouse)
- Known as:
- CD8a (mouse)
- Catalog number:
- 1F-579-C100
- Product Quantity:
- 0.1 mg
- Category:
- -
- Supplier:
- Exbio
- Gene target:
- CD8a (mouse)
Related genes to: CD8a (mouse)
- Gene:
- CD8A NIH gene
- Name:
- CD8a molecule
- Previous symbol:
- CD8
- Synonyms:
- -
- Chromosome:
- 2p11.2
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2019-04-23
Related products to: CD8a (mouse)
Related articles to: CD8a (mouse)
- Immune checkpoint inhibitors (ICI) are used to treat unresectable advanced or recurrent gastric cancer; however, reliable predictive biomarkers remain limited. This study aimed to identify biomarkers for predicting ICI efficacy using two independent cohorts. - Source: PubMed
Publication date: 2026/06/09
Ikeda ShinichiroHu QingjiangNatsugoe KeitaTanaka YasushiKawazoe TetsuroKashiwada TomomiMakiyama AkitakaAndo KojiOki EijiOda YoshinaoYoshizumi Tomoharu - T cell exhaustion (Tex) severely limits the efficacy of tumor immunotherapy, yet strategies targeting its upstream regulatory mechanisms remain underexplored. In this study, a targeted nanodelivery system, CD8a-RM-MOF@siSNX9, was developed to preferentially enrich siRNA delivery in CD8 T cells and evaluate its potential to reverse Tex in triple-negative breast cancer (TNBC). Using a 4T1-induced TNBC mouse model combined with RNA sequencing analysis, SNX9 was identified as a key regulator associated with Tex. Silencing SNX9 was accompanied by reduced NFATc2-NR4A1-TOX signaling, decreased exhaustion phenotypes, and enhanced cytokine secretion and cytotoxic activity of CD8 T cells. The nanoplatform exhibited prolonged circulation in vivo (t₁/₂ ≈ 12.4 h) and efficient tumor-targeted accumulation (~ 8.5%ID/g). Importantly, the nanoparticles preferentially accumulated in CD8 T cells within the tumor microenvironment, leading to SNX9 knockdown, attenuation of the NFATc2-NR4A1-TOX regulatory program, reversal of Tex, and significant suppression of TNBC tumor growth while maintaining favorable biosafety. Collectively, these findings demonstrate that CD8a-RM-MOF@siSNX9 represents a promising targeted siRNA delivery platform with preferential CD8 T-cell enrichment for targeting Tex and enhancing antitumor immunity in TNBC. - Source: PubMed
Publication date: 2026/06/04
Hu WeiChen QishuaiMa YanLiu YangQiu ShushengDong XianingZhu ZengjunWu XuanxuanDu JianxinXu YanbinTian MaojinZhao Peiqing - This study aimed to comparatively characterize the immune microenvironment (iME) in murine and human precursor lesions of pancreatic ductal adenocarcinoma (PDAC) to better understand its role in pancreatic carcinogenesis. - Source: PubMed
Publication date: 2026/06/03
Haeberle-Graser LSchulte MMueller CHaensch SSchlensog MEsposito I - Neuroinflammation is common in people with HIV (PWH) and may be reflected also in plasma biomarkers; the latter are sometimes used as surrogates for CSF. However, use of plasma biomarkers in this way risks obscuring compartment-specific processes since distribution across the blood-brain barrier (BBB) varies between proteins with some reaching the CNS more readily than others. We tested the hypothesis that BBB and viral suppression status shape cross-compartment biomarker coupling, clarifying when plasma proteins do or do not represent neuroinflammation. - Source: PubMed
Publication date: 2026/05/21
Ellis Ronald JTang BinRiggs Patricia KLudicello Jennifer EMarcondes Maria Cecilia GDelorme-Walker ViolaineHeaton Robert KLetendre Scott L - Psoriasis is a chronic, immune-mediated disorder with an unmet need for effective treatments. To systematically prioritize therapeutic targets, we integrated proteome-wide Mendelian randomization (MR) with expression validation in blood/skin, genetic susceptibility analysis in the UK Biobank, differential gene expression (DGE) from bulk and single-cell RNA sequencing (scRNA-seq), colocalization, pathway enrichment, and protein-protein interaction analyses. - Source: PubMed
Publication date: 2026/05/28
Si ShuchengWang XiaoxiaoZhan Siyan